

Cosentyx® (secukinumab) – New formulation approval

- On October 6, 2023, <u>Novartis announced</u> the FDA approval of an intravenous (IV) formulation of <u>Cosentyx (secukinumab)</u>, for the treatment of adults with active psoriatic arthritis (PsA), active ankylosing spondylitis (AS), and active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation.
- Cosentyx was previously approved as a subcutaneous (SC) injection. In addition to the indications listed above, the SC formulation of Cosentyx is also approved for the treatment of:
 - Moderate to severe plaque psoriasis in patients 6 years and older who are candidates for systemic therapy or phototherapy
 - Active PsA in pediatric patients 2 years of age and older
 - Active enthesitis-related arthritis (ERA) in pediatric patients 4 years of age and older.
- Cosentyx is the first IV formulation that specifically targets and blocks interleukin-17A (IL-17A).
- The recommended dose of IV Cosentyx across its different uses is 1.75 mg/kg every 4 weeks (maintenance dosage) (loading dose of 6 mg/kg given at week 0 may be given).
 - IV infusion is only for use by a healthcare professional in a healthcare setting.
 - Refer to the Cosentyx drug label for SC dosing.
- Novartis plans to launch IV Cosentyx in the fourth quarter 2023. Cosentyx will be available as a 125 mg/5 mL solution in a single-dose vial.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.